In a groundbreaking move, the FDA has approved a new drug, Kisunla (donanemab-azbt) which is a once-a-month injectable ...

Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same ...

Leqembi (lecanemab) and Kisunla (donanemab) are proven to slow cognitive and functional decline by 27 and 35%, respectively.

Scientists are testing an experimental anti-amyloid antibody in people expected to develop early-onset Alzheimer's.

Eli Lilly has chalked up another regulatory approval for its anti-amyloid therapy for Alzheimer's disease, Kisunla, in China – the world's second-largest pharma market. The National Medical ...

New drug approvals and a federal dementia care pilot program among the year's significant developments, according to the nonprofit.

Eli Lilly says a new starting dose regimen for its Alzheimer's disease therapy Kisunla reduces the risk of side effects that have stood in the way of approvals and reimbursement decisions for ...

Lecanemab, from Biogen and Japanese partner Eisai Co., is sold under the brand name Leqembi, and donanemab from Eli Lilly is branded as Kisunla. Both drugs work by reducing the brain amyloid ...

These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such ...

Eisai and Biogen, with Leqembi, and Eli Lilly, with Kisunla, have begun the process of establishing a drug arsenal for Alzheimer’s. Philippa Salter, managing neurology analyst at GlobalData ...

We believe cardiometabolic drugs Mounjaro, Zepbound, and Jardiance as well as immunology drug Taltz, cancer drug Verzenio, and Alzheimer's drug Kisunla hold the highest sales potential of Lilly's ...

1 Lilly defines new products as select products launched since 2022, which currently consist of Ebglyss, Jaypirca, Kisunla, Mounjaro, Omvoh and Zepbound. 2 Lilly defines Growth Products as ...